DNMT3A and acute myeloid leukemia: Taken together, these findings show that metformin use is associated with significantly reduced risk of DNMT3A-R882-mutant CH and propose this well-tolerated drug as a potential intervention to prevent or retard its clonal expansion and, in so doing, reduce the likelihood of progression to AML.